Cancer
Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer
January 31, 2019Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer
Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …
Read Pharmafocus January/February 2019 edition online now!
January 30, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Cancer, Counterfeit drugs, NHS, Pharmafocus, WHO, brexit, pharma, vaccines
We’re slowly edging towards warmer months, but the New Year brings more than just the promise of more amicable weather; …
Israeli biotech claims it has developed cure for cancer
January 30, 2019Research and Development Cancer, MuTaTo, biotech, israel, lung cancer, oncology
An Israeli biotech has claimed that it has developed a complete cure for cancer. Speaking to the Jerusalem Post, Dan …
Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia
January 29, 2019Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma
It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …
Precision cancer treatment for dogs moves towards human testing
January 29, 2019Manufacturing and Production CAR-T therapy, Cancer, Precision Medicine, car t therapy, dogs, t cells, t-cells
Scientists at the University of Missouri have developed a patient specific, precision medicine treatment for bone cancer in dogs. The …
People in England will be able to pay the NHS to sequence their genetic data, if they share it with scientists
January 28, 2019Sales and Marketing Alzheimer's, Cancer, England, NHS, genetic data, genomes, health
The NHS will provide paid-for health reports, informing patients as to the likelihood that they will develop diseases such as …
Diagnosis at stages 1-3 increases cancer survival rate significantly
January 25, 2019Medical Communications Cancer, England, NHS, health, oncology
Adults diagnosed with stage 1 skin, prostate or breast cancer have the same chance of still being alive the following …
EMA rejects Lilly’s Lartruvo in soft tissue cancer following trial failure
January 24, 2019Sales and Marketing Cancer, EMA, Eli Lilly, Lartruvo, pharma
Eli Lilly has been dealt a blow as the European Medicines Agency announced its recommendation for soft tissue cancer patients …
GSK acquires oncology firm Tesaro for $5.1 billion
January 23, 2019Research and Development Cancer, GSK, Tesaro, oncology, ovarian cancer
British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion). Tesaro, a Massachusetts-based clinical stage …
Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia
January 23, 2019Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma
The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …
Pushing for progress in mesothelioma
January 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, mesothelioma, pharma
Mesothelioma.net reviews the wide array of latest advances in treatment and care for patients affected by the challenging cancer as …
Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma
January 21, 2019Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure
Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …
NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma
January 21, 2019Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma
Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …
Canada Health approves Novartis’ CAR-T therapy Kymriah
January 18, 2019Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology
Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …
Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer
January 17, 2019Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma
Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …
Latest content
Five Facts about cardiovascular disease
